Clinical Trials /

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703

Description:

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.

Related Conditions:
  • Breast Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
  • Official Title: MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Clinical Trial IDs

  • ORG STUDY ID: 15362
  • SECONDARY ID: I3Y-MC-JPBL
  • SECONDARY ID: 2013-004728-13
  • NCT ID: NCT02107703

Conditions

  • Breast Neoplasms

Interventions

DrugSynonymsArms
AbemaciclibLY2835219Abemaciclib + Fulvestrant
FulvestrantAbemaciclib + Fulvestrant
PlaceboPlacebo + Fulvestrant

Purpose

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib+fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant.

Trial Arms

NameTypeDescriptionInterventions
Abemaciclib + FulvestrantExperimental150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
  • Abemaciclib
  • Fulvestrant
Placebo + FulvestrantPlacebo ComparatorPlacebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
  • Fulvestrant
  • Placebo

Eligibility Criteria

        Inclusion Criteria

          -  Have a diagnosis of HR+, HER2- breast cancer

          -  Have locally advanced disease not amenable to curative treatment by surgery or
             metastatic disease. In addition, participants must fulfill 1 of the following
             criteria:

               -  relapsed with radiologic evidence of progression while receiving neoadjuvant or
                  adjuvant endocrine therapy, with no subsequent endocrine therapy received
                  following progression

               -  relapsed with radiologic evidence of progression within 1 year from completion of
                  adjuvant endocrine therapy, with no subsequent endocrine therapy received
                  following progression

               -  relapsed with radiologic evidence of progression more than 1 year from completion
                  of adjuvant endocrine therapy and then subsequently relapsed with radiologic
                  evidence of progression after receiving treatment with either an antiestrogen or
                  an aromatase inhibitor as first-line endocrine therapy for metastatic disease.
                  Participants may not have received more than 1 line of endocrine therapy or any
                  prior chemotherapy for metastatic disease

               -  presented de novo with metastatic disease and then relapsed with radiologic
                  evidence of progression after receiving treatment with either an antiestrogen or
                  an aromatase inhibitor as first line endocrine therapy for metastatic disease.
                  Participants may not have received more than 1 line of endocrine therapy or any
                  prior chemotherapy for metastatic disease

          -  Have postmenopausal status due to either surgical/natural menopause or ovarian
             suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a
             gonadotropin-releasing hormone (GnRH) agonist such as goserelin

          -  Have a negative serum pregnancy test at baseline (within 14 days prior to
             randomization) and agree to use medically approved precautions to prevent pregnancy
             during the study and for 12 weeks following the last dose of abemaciclib if
             postmenopausal status is due to ovarian suppression with a GnRH agonist

          -  Have either measurable disease or nonmeasurable bone only disease

          -  Have a performance status ≤1 on the ECOG scale

          -  Have discontinued previous therapies for cancer (including specifically, aromatase
             inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at
             least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents
             prior to receiving study drug, and recovered from the acute effects of therapy (until
             the toxicity resolves to either baseline or at least Grade 1) except for residual
             alopecia or peripheral neuropathy

        Exclusion Criteria

          -  Are currently receiving an investigational drug in a clinical trial or participating
             in any other type of medical research judged not to be scientifically or medically
             compatible with this study

          -  Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis visceral
             crisis is not the mere presence of visceral metastases but implies severe organ
             dysfunction as assessed by symptoms and signs, laboratory studies, and rapid
             progression of the disease

          -  Have clinical evidence or history of central nervous system metastasis

          -  Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant
             chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days prior to randomization of study drug for a
             nonmyelosuppressive or myelosuppressive agent, respectively

          -  Have received recent (within 28 days prior to randomization) yellow fever vaccination

          -  Have had major surgery within 14 days prior to randomization of study drug to allow
             for post-operative healing of the surgical wound and site(s)

          -  Have a personal history within the last 12 months of any of the following conditions:
             syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation,
             or sudden cardiac arrest

          -  Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma
             skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no
             therapy for a minimum of 3 years

          -  Have received an autologous or allogeneic stem-cell transplant

          -  Have active bacterial or fungal infection, or detectable viral infection

          -  Have initiated bisphosphonates or approved Receptor activator of nuclear factor
             kappa-B (RANK) ligand targeted agents <7 days prior to randomization
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:Progression-Free Survival (PFS)
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Overall Survival (OS)
Time Frame:Baseline up to Approximately 80 Months
Safety Issue:
Description:
Measure:Objective Response Rate
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:
Measure:Duration of Response (DoR)
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:
Measure:Disease Control Rate (DCR)
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:
Measure:Clinical Benefit Rate (CBR)
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:
Measure:Change from Baseline in Pain and Symptom Burden Assessment Using the Brief Pain Inventory (BPI)
Time Frame:Baseline, End of Study (up to approximately 31 months)
Safety Issue:
Description:
Measure:Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Abemaciclib, Its Metabolites, and Fulvestrant
Time Frame:Baseline up to Approximately 31 Months
Safety Issue:
Description:
Measure:Change from Baseline in Health Status Using the EuroQol 5-Dimension 5 Level (EQ-5D 5L)
Time Frame:Baseline, End of Study (up to approximately 31 months)
Safety Issue:
Description:
Measure:Change from Baseline in Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time Frame:Baseline, End of Study (up to approximately 31 months)
Safety Issue:
Description:
Measure:Change from Baseline in Quality of Life Using the EORTC QLQ-BR23 (breast) Questionnaire
Time Frame:Baseline, End of Study (up to approximately 31 months)
Safety Issue:
Description:

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:Eli Lilly and Company

Trial Keywords

  • MONARCH 2

Last Updated

June 14, 2017